Daniel Hübschmann Selected Research

Daniel Hübschmann Research Topics

Disease

21	Neoplasms (Cancer) 01/2024 - 11/2016
4	Sarcoma (Soft Tissue Sarcoma) 01/2022 - 11/2016
2	Acute Myeloid Leukemia (Acute Myelogenous Leukemia) 10/2023 - 01/2021
2	Medulloblastoma 12/2021 - 01/2017
2	Chromothripsis 12/2021 - 10/2018
1	Solitary Fibrous Tumors 01/2024
1	Rhabdomyosarcoma 01/2024
1	Thrombocytopenia (Thrombopenia) 01/2024
1	Neutropenia 01/2024
1	Hematologic Neoplasms (Hematological Malignancy) 10/2023
1	Hyperprolactinemia 07/2023
1	Adrenocortical Carcinoma 06/2023
1	Parathyroid Neoplasms (Parathyroid Neoplasm) 01/2023
1	Cholangiocarcinoma 12/2022
1	Biliary Tract Neoplasms (Biliary Tract Cancer) 01/2022
1	Pancreatic Neoplasms (Pancreatic Cancer) 01/2021
1	Movement Disorders (Movement Disorder) 01/2021
1	Lymphatic Metastasis 01/2021
1	Alveolar Rhabdomyosarcoma 12/2020
1	Liposarcoma 12/2020
1	Extraskeletal Myxoid Chondrosarcoma 12/2020
1	Ewing Sarcoma (Sarcoma, Ewing) 12/2020
1	Synovial Sarcoma (Synovioma) 12/2020
1	Myxoid Liposarcoma 12/2020
1	Clear Cell Sarcoma 12/2020
1	Neoplasm Metastasis (Metastasis) 01/2019
1	Burkitt Lymphoma (Burkitt's Lymphoma) 01/2019
1	Glioblastoma (Glioblastoma Multiforme) 01/2019
1	Genomic Instability 01/2019
1	Chordoma 01/2019
1	Prostatic Neoplasms (Prostate Cancer) 01/2019

Drug/Important Bio-Agent (IBA)

6	RNA (Ribonucleic Acid)IBA 10/2023 - 01/2017
5	DNA (Deoxyribonucleic Acid)IBA 01/2024 - 01/2017
5	Biomarkers (Surrogate Marker)IBA 01/2024 - 01/2019
3	Poly(ADP-ribose) Polymerase InhibitorsIBA 12/2021 - 01/2019
3	olaparibIBA 01/2019 - 10/2018
2	Proteins (Proteins, Gene)FDA Link 01/2024 - 12/2022
2	Messenger RNA (mRNA)IBA 01/2024 - 11/2016
2	Neurotransmitter Agents (Neurotransmitter)IBA 07/2023 - 01/2021
2	Immune Checkpoint InhibitorsIBA 06/2023 - 11/2016
2	Poly(ADP-ribose) Polymerases (Poly ADP Ribose Polymerase)IBA 01/2021 - 01/2019
1	FAPI-46IBA 01/2024
1	Fluorodeoxyglucose F18 (Fludeoxyglucose F 18)FDA Link 01/2024
1	Carboplatin (JM8)FDA LinkGeneric 01/2024
1	adavosertibIBA 01/2024
1	MicroRNAs (MicroRNA)IBA 10/2023
1	Cytarabine (Cytosar-U)FDA LinkGeneric 10/2023
1	Daunorubicin (Cerubidine)FDA LinkGeneric 10/2023
1	Genetic Markers (Genetic Marker)IBA 10/2023
1	Cabergoline FDA LinkGeneric 07/2023
1	Dopamine Agonists (Dopamine Agonist)IBA 07/2023
1	Levodopa (L Dopa)FDA LinkGeneric 07/2023
1	Biogenic Amines (Biogenic Amine)IBA 07/2023
1	naporafenibIBA 01/2023
1	Oncogene Proteins (Oncogene Protein)IBA 01/2023
1	6-propylchromone-2-carboxylic acid (PCCA)IBA 12/2022
1	tyrosine receptor (receptor, tyrosine)IBA 01/2022
1	pazopanib FDA Link 01/2022
1	CarbonIBA 12/2021
1	IonsIBA 12/2021
1	pembrolizumabIBA 01/2021
1	Cell-Free Nucleic AcidsIBA 12/2020
1	Succinic Acid (Succinate)IBA 10/2020
1	FumaratesIBA 10/2020
1	NucleotidesIBA 01/2019
1	Isocitrate Dehydrogenase (Isocitrate Dehydrogenase (NAD+))IBA 01/2019
1	Complement System Proteins (Complement)IBA 01/2019
1	PlatinumIBA 01/2019
1	Cisplatin (Platino)FDA LinkGeneric 10/2018

Therapy/Procedure

17	Therapeutics 01/2024 - 11/2016
6	Drug Therapy (Chemotherapy) 10/2023 - 11/2016
3	Immunotherapy 06/2023 - 01/2021
1	Precision Medicine 10/2023
1	Radiotherapy 12/2021
1	Heavy Ion Radiotherapy 12/2021